Audited Financial Results for the quarter and year ended 31st March, 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Ishita Drugs & Industries Ltd has reported audited financial results for Q4 and FY 2025-26. The company received an unmodified (clean) audit opinion from statutory auditors JM Shah & Associates. Total assets decreased from Rs 16.30 crore to Rs 12.60 crore year-on-year, while total equity increased from Rs 10.79 crore to Rs 11.57 crore. Total liabilities saw a significant reduction from Rs 5.51 crore to Rs 1.04 crore. Cash and cash equivalents dropped from Rs 56.84 lakhs to Rs 14.56 lakhs. Net cash generated from operating activities was Rs 3.92 crore, up from Rs 3.64 crore in the prior year. Capital work-in-progress stood at Rs 1.75 crore indicating ongoing investment in assets.
The company demonstrated strong balance sheet improvement with debt reduction and equity growth. Positive operating cash flow is encouraging, though the significant decline in cash reserves and total assets warrants monitoring. The clean audit opinion provides assurance on financial reporting quality.